RecruitingPhase 4NCT01818661

Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech


Sponsor

Mayo Clinic

Enrollment

50 participants

Start Date

Jul 1, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This Mayo Clinic study uses multi-modality brain imaging (MRI and PET scans) to track brain changes over time in people with progressive apraxia of speech (AOS) — a neurological condition affecting the ability to plan and sequence movements needed for speaking, distinct from aphasia or dysarthria. The goal is to better understand how the condition progresses. You may be eligible if: - You are 18 years or older - You have been diagnosed with neurodegenerative apraxia of speech at Mayo Clinic - You have an available informant (someone who knows you well) You may NOT be eligible if: - Your speech/language problems are caused by another condition (stroke, brain injury, developmental syndrome) - You are pregnant, postpartum, or breastfeeding - You have contraindications to MRI (e.g., pacemaker, metal in the head, severe claustrophobia) - You take medications that might affect brain structure or metabolism (e.g., chemotherapy) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAV-1451

This is used to assess Tau burden in the brain.


Locations(1)

Mayo Clinic

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01818661


Related Trials